Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145610847> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2145610847 endingPage "A251" @default.
- W2145610847 startingPage "A251" @default.
- W2145610847 abstract "Short-term cost per outcome analyses focusing on efficient attainment of desired health care outcomes, including quality measures can be useful decision-making tools for managed-care payers. Therefore, a simple cost-efficiency model was developed to compare the short-term (i.e., 1-year) clinical and economic outcomes of treating hyperglycemia with canagliflozin versus sitagliptin in people with T2DM. Data on clinical efficacy and key adverse events (AEs) were obtained from a pooled analysis of 2 comparative trials of canagliflozin 300 mg/day versus sitagliptin100 mg/day. Wholesale drug acquisition costs were used. The total and diabetes-related cost savings associated with achieving (vs. not achieving) A1C<7% was specified as $3,055/year and $1,651/year, respectively, based on previously reported claims database analysis. Savings of $288/year associated with 1% decrease in weight, sourced from the literature was applied. AE-related costs (i.e., $105-$154/genital mycotic infections and $532/hypoglycemia requiring third-party assistance) were derived from treatment algorithms, literature, and reimbursement rates. Total costs, average and incremental costs/key outcomes were calculated. In the simplest analysis evaluating drug cost/outcome only, where annual drug-related costs were similar (canagliflozin 300 mg $3,660 vs sitagliptin $3,594), the average cost/patient achieving A1C<7% were lower for canagliflozin 300 mg compared to sitagliptin ($7,162 vs $8,398/patient per year, respectively). Likewise, the average cost per 1% reduction in A1C were lower for canagliflozin 300 mg versus sitagliptin ($3,893 vs $5,364). In a comprehensive analysis including medical, drug, and adverse event costs, canagliflozin 300 mg dominates sitagliptin in incremental cost efficiency in A1C goals. Canagliflozin 300 mg resulted in net savings of $639 per patient / year compared to sitagliptin. Based on inputs and assumptions used in this model, this 52-week economic analysis suggests that canagliflozin 300mg is likely to be a cost-saving treatment option compared with sitagliptin 100 mg when used in combination with other antihyperglycemic agents to treat T2DM." @default.
- W2145610847 created "2016-06-24" @default.
- W2145610847 creator A5014760955 @default.
- W2145610847 creator A5017994555 @default.
- W2145610847 creator A5024416755 @default.
- W2145610847 creator A5028462465 @default.
- W2145610847 creator A5028629925 @default.
- W2145610847 creator A5053644252 @default.
- W2145610847 date "2014-05-01" @default.
- W2145610847 modified "2023-09-29" @default.
- W2145610847 title "Short-term economic and clinical outcomes of canagliflozin compared to sitagliptin in the management of type 2 diabetes mellitus (t2dm)" @default.
- W2145610847 doi "https://doi.org/10.1016/j.jval.2014.03.1463" @default.
- W2145610847 hasPublicationYear "2014" @default.
- W2145610847 type Work @default.
- W2145610847 sameAs 2145610847 @default.
- W2145610847 citedByCount "0" @default.
- W2145610847 crossrefType "journal-article" @default.
- W2145610847 hasAuthorship W2145610847A5014760955 @default.
- W2145610847 hasAuthorship W2145610847A5017994555 @default.
- W2145610847 hasAuthorship W2145610847A5024416755 @default.
- W2145610847 hasAuthorship W2145610847A5028462465 @default.
- W2145610847 hasAuthorship W2145610847A5028629925 @default.
- W2145610847 hasAuthorship W2145610847A5053644252 @default.
- W2145610847 hasBestOaLocation W21456108471 @default.
- W2145610847 hasConcept C121332964 @default.
- W2145610847 hasConcept C126322002 @default.
- W2145610847 hasConcept C134018914 @default.
- W2145610847 hasConcept C177713679 @default.
- W2145610847 hasConcept C2777451236 @default.
- W2145610847 hasConcept C2779284873 @default.
- W2145610847 hasConcept C2910068830 @default.
- W2145610847 hasConcept C555293320 @default.
- W2145610847 hasConcept C61797465 @default.
- W2145610847 hasConcept C62520636 @default.
- W2145610847 hasConcept C71924100 @default.
- W2145610847 hasConceptScore W2145610847C121332964 @default.
- W2145610847 hasConceptScore W2145610847C126322002 @default.
- W2145610847 hasConceptScore W2145610847C134018914 @default.
- W2145610847 hasConceptScore W2145610847C177713679 @default.
- W2145610847 hasConceptScore W2145610847C2777451236 @default.
- W2145610847 hasConceptScore W2145610847C2779284873 @default.
- W2145610847 hasConceptScore W2145610847C2910068830 @default.
- W2145610847 hasConceptScore W2145610847C555293320 @default.
- W2145610847 hasConceptScore W2145610847C61797465 @default.
- W2145610847 hasConceptScore W2145610847C62520636 @default.
- W2145610847 hasConceptScore W2145610847C71924100 @default.
- W2145610847 hasIssue "3" @default.
- W2145610847 hasLocation W21456108471 @default.
- W2145610847 hasOpenAccess W2145610847 @default.
- W2145610847 hasPrimaryLocation W21456108471 @default.
- W2145610847 hasRelatedWork W189524908 @default.
- W2145610847 hasRelatedWork W1965466979 @default.
- W2145610847 hasRelatedWork W2096303420 @default.
- W2145610847 hasRelatedWork W2283517602 @default.
- W2145610847 hasRelatedWork W2317443355 @default.
- W2145610847 hasRelatedWork W2331539689 @default.
- W2145610847 hasRelatedWork W2331819439 @default.
- W2145610847 hasRelatedWork W2339683554 @default.
- W2145610847 hasRelatedWork W2343465675 @default.
- W2145610847 hasRelatedWork W2493655186 @default.
- W2145610847 hasRelatedWork W2518492470 @default.
- W2145610847 hasRelatedWork W2604667662 @default.
- W2145610847 hasRelatedWork W2787518873 @default.
- W2145610847 hasRelatedWork W2903207239 @default.
- W2145610847 hasRelatedWork W2920395247 @default.
- W2145610847 hasRelatedWork W3098093747 @default.
- W2145610847 hasRelatedWork W3115651139 @default.
- W2145610847 hasRelatedWork W3116488653 @default.
- W2145610847 hasRelatedWork W2136348544 @default.
- W2145610847 hasRelatedWork W2182009280 @default.
- W2145610847 hasVolume "17" @default.
- W2145610847 isParatext "false" @default.
- W2145610847 isRetracted "false" @default.
- W2145610847 magId "2145610847" @default.
- W2145610847 workType "article" @default.